Jade Biosciences Inc Financials

JBIO

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Jade Biosciences Inc (JBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Jade Biosciences Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.74x

For every $1 of reported earnings, Jade Biosciences Inc generates $0.74 in operating cash flow (-$94.7M OCF vs -$127.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$113.5M

YoY-52.8%

Jade Biosciences Inc's EBITDA was -$113.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.8% from the prior year.

Free Cash Flow

-$94.9M

Jade Biosciences Inc generated -$94.9M in free cash flow in fiscal year 2025, representing cash available after capex.

Net Income

-$127.4M

YoY-83.0%

Jade Biosciences Inc reported -$127.4M in net income in fiscal year 2025. This represents a decrease of 83.0% from the prior year.

EPS (Diluted)

$-3.19

Jade Biosciences Inc earned $-3.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 30.7% from the prior year.

Cash & Debt

$88.4M

YoY+27.5%

5Y CAGR+80.8%

Jade Biosciences Inc held $88.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

49M

Jade Biosciences Inc had 49M shares outstanding in fiscal year 2025. This represents an increase of 1242.7% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$93.1M

YoY+75.1%

5Y CAGR+63.6%

Jade Biosciences Inc invested $93.1M in research and development in fiscal year 2025. This represents an increase of 75.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$196K

Jade Biosciences Inc invested $196K in capex in fiscal year 2025, funding long-term assets and infrastructure.

JBIO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$93.1M+75.1%	$53.2M-17.2%	$64.2M+66.3%	$38.6M+157.7%	$15.0M+88.8%	$7.9M
SG&A Expenses	$20.4M-4.6%	$21.4M+24.5%	$17.2M+17.6%	$14.6M+81.9%	$8.0M+746.7%	$949K
Operating Income	-$113.5M-52.2%	-$74.6M+8.4%	-$81.4M-52.9%	-$53.2M-131.2%	-$23.0M-159.0%	-$8.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$75K
Income Tax	$58K+5.5%	$55K-1.8%	$56K+124.0%	$25K+733.3%	$3K	N/A
Net Income	-$127.4M-83.0%	-$69.6M+7.8%	-$75.5M-46.6%	-$51.5M-124.3%	-$23.0M-138.9%	-$9.6M
EPS (Diluted)	$-3.19	$-2.44	$-2.87-36.7%	$-2.10-12.3%	$-1.87	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$22.0M-2.4%	$22.5M	N/A	N/A	$13.6M-36.1%	$21.2M+5.8%	$20.1M
SG&A Expenses	N/A	$5.4M+3.1%	$5.2M+54.4%	$3.4M	N/A	$1.4M-71.9%	$4.9M+8.4%	$4.5M
Operating Income	N/A	-$27.4M+1.4%	-$27.8M-720.1%	-$3.4M	N/A	-$15.0M+42.8%	-$26.2M-6.3%	-$24.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	N/A	N/A	$0	N/A	N/A
Net Income	N/A	-$25.2M+21.7%	-$32.1M+15.8%	-$38.2M	N/A	-$16.3M+34.3%	-$24.8M-6.9%	-$23.2M
EPS (Diluted)	N/A	$-0.48+44.2%	$-0.86-855.6%	$-0.09	N/A	$-5.16-500.0%	$-0.86-3.6%	$-0.83

JBIO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$349.8M+380.5%	$72.8M-42.9%	$127.4M-5.8%	$135.3M-22.8%	$175.4M+3619.3%	$4.7M
Current Assets	$348.8M+400.8%	$69.7M-43.9%	$124.2M-5.5%	$131.5M-24.6%	$174.3M+3628.3%	$4.7M
Cash & Equivalents	$88.4M+27.5%	$69.4M+195.4%	$23.5M+4.9%	$22.4M-58.7%	$54.2M+1085.2%	$4.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$17.3M-85.6%	$119.6M+565.8%	$18.0M+109.9%	$8.6M+190.6%	$2.9M-83.7%	$18.1M
Current Liabilities	$16.5M+37.9%	$12.0M-32.0%	$17.6M+126.6%	$7.8M+205.2%	$2.5M+43.7%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$332.5M+810.5%	-$46.8M-142.8%	$109.5M-13.6%	$126.7M-26.5%	$172.4M+1392.1%	-$13.3M
Retained Earnings	-$174.4M-271.2%	-$47.0M+71.3%	-$163.4M-85.9%	-$87.9M-141.5%	-$36.4M-171.4%	-$13.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$349.8M+72.8%	$202.4M-9.6%	$224.0M+188.9%	$77.5M+6.5%	$72.8M-20.0%	$91.0M-18.6%	$111.7M+4.6%	$106.8M
Current Assets	$348.8M+73.2%	$201.4M-9.7%	$223.0M+188.2%	$77.4M+11.1%	$69.7M-23.1%	$90.6M-18.2%	$110.8M+7.3%	$103.2M
Cash & Equivalents	$88.4M+76.5%	$50.1M-77.3%	$220.9M+399.6%	$44.2M-36.3%	$69.4M+123.0%	$31.1M+0.1%	$31.1M+240.6%	$9.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$17.3M-25.3%	$23.1M+3.1%	$22.4M-86.1%	$161.0M+34.7%	$119.6M+10.9%	$107.8M-4.0%	$112.3M+605.4%	$15.9M
Current Liabilities	$16.5M-26.0%	$22.4M+3.4%	$21.6M+794.5%	$2.4M-79.9%	$12.0M+16.3%	$10.3M-39.4%	$17.0M+9.7%	$15.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$332.5M+85.4%	$179.3M-11.0%	$201.6M+341.4%	-$83.5M-78.4%	-$46.8M-177.5%	-$16.9M-2763.0%	-$589K-100.6%	$90.9M
Retained Earnings	-$174.4M-22.4%	-$142.5M-21.5%	-$117.3M+50.2%	-$235.6M-401.4%	-$47.0M+79.4%	-$227.6M-7.7%	-$211.4M-13.3%	-$186.6M

JBIO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$94.7M-33.0%	-$71.2M-25.4%	-$56.8M-45.1%	-$39.1M-42.8%	-$27.4M-248.6%	-$7.9M
Capital Expenditures	$196K	N/A	$142K-27.2%	$195K+7.7%	$181K	N/A
Free Cash Flow	-$94.9M	N/A	-$56.9M-44.8%	-$39.3M-42.6%	-$27.6M	N/A
Investing Cash Flow	-$247.0M-540.9%	$56.0M+371.8%	$11.9M+71.5%	$6.9M+106.1%	-$113.4M	N/A
Financing Cash Flow	$360.8M+1318.8%	$25.4M-44.7%	$46.0M+11515.2%	$396K-99.8%	$190.5M+2035.6%	$8.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$33.6M-52.1%	-$22.1M+39.4%	-$36.5M-1434.4%	-$2.4M+78.4%	-$11.0M-62.4%	-$6.8M+66.7%	-$20.4M+13.7%	-$23.7M
Capital Expenditures	$3K-94.7%	$57K	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$33.7M-51.7%	-$22.2M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$98.2M+34.0%	-$148.7M-1045.1%	-$13.0M-201.1%	$12.8M-2.1%	$13.1M	$0-100.0%	$18.0M+103.8%	$8.8M
Financing Cash Flow	$170.2M	$0	N/A	N/A	$554K-99.4%	$94.8M+288.7%	$24.4M+5076.2%	$471K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JBIO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-36.4%+59.2pp	-95.6%-36.4pp	-59.3%-21.2pp	-38.1%-25.0pp	-13.1%+190.8pp	-203.8%
Current Ratio	21.09+15.3	5.81-1.2	7.04-9.9	16.90-51.5	68.37+65.7	2.64
Debt-to-Equity	0.05+2.6	-2.56-2.7	0.16+0.1	0.07+0.1	0.02+1.4	-1.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-12.4%+1.9pp	-14.3%+34.9pp	-49.2%	N/A	-17.9%+4.3pp	-22.2%-0.5pp	-21.7%
Current Ratio	21.09+12.1	9.01-1.3	10.31-21.7	32.01+26.2	5.81-3.0	8.78+2.3	6.51-0.1	6.65
Debt-to-Equity	0.05-0.1	0.13+0.0	0.11+2.0	-1.93+0.6	-2.56+3.8	-6.39+184.2	-190.63-190.8	0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Atea Pharmaceuticals, Inc. AVIR

$472.7M

Rapt Therapeutics, Inc. RAPT

$1.7B

Allogene Therapeutics ALLO

$609.0M

Cartesian RNAC

$222.3M

Invivyd IVVD

$516.0M

Frequently Asked Questions

Is Jade Biosciences Inc profitable?

No, Jade Biosciences Inc (JBIO) reported a net income of -$127.4M in fiscal year 2025.

What is Jade Biosciences Inc's earnings per share (EPS)?

Jade Biosciences Inc (JBIO) reported diluted earnings per share of $-3.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Jade Biosciences Inc's EBITDA?

Jade Biosciences Inc (JBIO) had EBITDA of -$113.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jade Biosciences Inc's free cash flow?

Jade Biosciences Inc (JBIO) generated -$94.9M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jade Biosciences Inc's operating cash flow?

Jade Biosciences Inc (JBIO) generated -$94.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jade Biosciences Inc's total assets?

Jade Biosciences Inc (JBIO) had $349.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Jade Biosciences Inc's capital expenditures?

Jade Biosciences Inc (JBIO) invested $196K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Jade Biosciences Inc spend on research and development?

Jade Biosciences Inc (JBIO) invested $93.1M in research and development during fiscal year 2025.

How many shares does Jade Biosciences Inc have outstanding?

Jade Biosciences Inc (JBIO) had 49M shares outstanding as of fiscal year 2025.

What is Jade Biosciences Inc's current ratio?

Jade Biosciences Inc (JBIO) had a current ratio of 21.09 as of fiscal year 2025, which is generally considered healthy.

What is Jade Biosciences Inc's debt-to-equity ratio?

Jade Biosciences Inc (JBIO) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jade Biosciences Inc's return on assets (ROA)?

Jade Biosciences Inc (JBIO) had a return on assets of -36.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jade Biosciences Inc's cash runway?

Based on fiscal year 2025 data, Jade Biosciences Inc (JBIO) had $88.4M in cash against an annual operating cash burn of $94.7M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Jade Biosciences Inc's Piotroski F-Score?

Jade Biosciences Inc (JBIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jade Biosciences Inc's earnings high quality?

Jade Biosciences Inc (JBIO) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.